Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 18/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 15/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL536774 | 0.83 | KEAP1 (0.38) | ADORA2AADORA1ALDH1A1KEAP1NFE2L2 | |
| SCHEMBL7151666 | 0.81 | ADORA2A (0.51) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL7152758 | 0.75 | ADORA2A (0.51) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL4052390 | 0.74 | ADORA2A (0.60) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL7152635 | 0.74 | ADORA2A (0.49) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL4046354 | 0.73 | ADORA2A (0.48) | ADORA2AADORA1ALDH1A1ADORA3ADORA2B | |
| SCHEMBL4046360 | 0.73 | ADORA2A (0.48) | ADORA2AADORA1ALDH1A1ADORA3ADORA2B | |
| SCHEMBL13322066 | 0.73 | ADORA2A (0.62) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL7151573 | 0.73 | ADORA2A (0.49) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL5039831 | 0.73 | MGMT (0.65) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130515-A1 | Polymorphs and solvates of a pharmaceutical and method of making | BIOGEN IDEC INC. (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100130515-A1 | Polymorphs and solvates of a pharmaceutical and method of making | BIOGEN IDEC INC. (US) | 2010-05-27 | — | — | US | disclosed |
| US-7589097-B2 | Triazol[4,5-d] pyramidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2009-09-15 | — | — | US | disclosed |
| EP-1392312-B1 | TRIAZOLO 4,5-d PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RES LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| US-20080234296-A1 | Triazolo[4,5-d] pyramidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED | 2008-09-25 | — | — | US | disclosed |
| WO-2008086201-A1 | POLYMORPHS AND SOLVATES OF A PHARMACEUTICAL AND METHODS OF MAKING | BIOGEN IDEC MA INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| US-7141575-B2 | Triazolo[4,5-d]pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LTD. (GB) | 2006-11-28 | — | — | US | disclosed |
| US-20040097526-A1 | Triazolo[4,5-d]pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS DEVELOPMENT LIMITED (GB) | 2004-05-20 | — | — | US | disclosed |
| EP-1392312-A1 | TRIAZOLO 4,5-d] PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002055083-A1 | TRIAZOLO[4,5-d] PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234296-A1 | Triazolo[4,5-d] pyramidine derivatives and their use as purinergic receptor antagonists | CHRNA5, ADORA2A, CHRNA4 | ADORA2A 2/4885ADORA1 10/4885ALDH1A1 2013/4885 |
| US-20100130515-A1 | Polymorphs and solvates of a pharmaceutical and method of making | CYP3A7, CYP2D6, CYP3A5 | ADORA2A 832/4885ADORA1 1274/4885ALDH1A1 508/4885 |
| US-20040097526-A1 | Triazolo[4,5-d]pyrimidine derivatives and their use as purinergic receptor antagonists | CHRNA5, CHRNA4, CNR1 | ADORA2A 7/4885ADORA1 19/4885ALDH1A1 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.